Clinical Trial Research
CytRx Reports Favorable Safety and Tolerability Results from High Dose, 28-Day Clinical Trial with Arimoclomol
Published in Medical Letter on the CDC and FDA, December 9th, 2007
CytRx believes that results from this clinical trial, together with previously-announced clinical data from a rising multiple dose study reported in June 2007, support the use of arimoclomol in future clinical trials, including its planned ALS Phase IIb...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- West Nile Virus
Earlier bites by uninfected mosquitoes boost West Nile deaths in lab mice - Gastroenteritis
New Data Published in the Lancet Show GSK's ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types - Keloid
Research on keloid published by W.G. Chernoff et al - Myeloma
Updated REVLIMID(R) (Lenalidomide) Plus Dexamethasone Data in Previously Treated Multiple Myeloma Reported in the New England Journal of Medicine - Pediatrics
InViragen Receives Funding From the Pediatric Dengue Vaccine Initiative - Rotavirus
AVANT's Partner, GlaxoSmithKline, Announces New Data Published in the Lancet Show That Rotarix(R) Provides Sustained and Broad Protection During the First Two Years of Life(1) - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
